Clinical Trials for Pancreas Cancer

A Phase II Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: Adults with ECOG 0–2 and measurable disease in three cohorts: refractory pancreatic adenocarcinoma/adenosquamous carcinoma; high-grade (Ki-67 >20%) pancreatic or GI neuroendocrine neoplasms post–≥1 line; or metastatic neuroendocrine prostate carcinoma after ≥1 line, receive oral ESK981 monotherapy (5 days on/2 off). ESK981 is a multitarget TKI with anti-angiogenic activity (VEGFR1/2/3, TIE-2) and PIKfyve inhibition (autophagy/immune modulation).

ClinicalTrials.gov ID: NCT05988918

Phase Ib/II Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of 'Switch Maintenance' Combination Immunotherapy Using AB154, AB122, and APX005M in Patients With Metastatic Pancreatic Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with metastatic pancreatic adenocarcinoma/squamous histology who have at least stable disease after 4–6 months of first‑line FOLFIRINOX are randomized to switch‑maintenance immunotherapy with domvanalimab (anti‑TIGIT) + zimberelimab (anti‑PD‑1) + APX005M/sotigalimab (CD40 agonist) versus continued maintenance FOLFIRI. Key exclusions include progression on FOLFIRINOX, prior checkpoint or CD40 therapy, significant autoimmune disease, active HBV/HCV/HIV, and germline BRCA1/2 mutations; crossover to the immunotherapy arm at progression is allowed.

ClinicalTrials.gov ID: NCT05419479

A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with nonmetastatic, locally advanced pancreatic adenocarcinoma after 4–6 months of induction chemotherapy (FOLFIRINOX, NALIRIFOX, or gemcitabine/nab-paclitaxel), ECOG 0–2, and planned non-operative management receive hypofractionated radiotherapy with or without oral peposertib. Peposertib is a selective DNA-PK inhibitor and radiosensitizer given concurrently for 14 days to enhance radiation efficacy; phase 2 randomizes against placebo.

ClinicalTrials.gov ID: NCT04172532

Phase 1 Clinical Trial of Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with locally advanced, unresectable pancreatic ductal adenocarcinoma (ECOG 0–2) after ≥4 months of multiagent chemotherapy and no metastases undergo surgical irreversible electroporation (IRE) with concurrent intratumoral mitazalimab, an agonistic CD40 monoclonal antibody aimed at activating dendritic cells and enhancing antitumor T-cell priming. Excludes prior pancreatic radiation, prior CD40 therapy, active autoimmune disease, implanted cardiac devices/metal, or tumors >4 cm or not amenable to complete IRE.

ClinicalTrials.gov ID: NCT06205849

A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Previously untreated adults with metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) receive gemcitabine plus nab-paclitaxel combined with avutometinib, a dual RAF/MEK inhibitor, and defactinib, a focal adhesion kinase (FAK) inhibitor. Dose-escalation followed by expansion assesses safety and preliminary antitumor activity; excludes prior systemic therapy for metastatic PDAC and prior RAF/MEK/FAK inhibitors.

ClinicalTrials.gov ID: NCT05669482

Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced/refractory solid tumors or lymphomas (all B- and T-cell subtypes except NK-cell) receive oral ZEN003694 (pan-BET bromodomain inhibitor targeting BRD2/3/4/BRDT) plus entinostat (class I HDAC inhibitor) after a brief monotherapy run-in; phase 2 focuses on unresectable/metastatic pancreatic cancer refractory to standard therapy. Combination is given in 28‑day cycles until progression or toxicity; treated/stable brain mets allowed, ECOG 0–2, prior systemic therapy required.

ClinicalTrials.gov ID: NCT05053971

A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with survivin-positive, radiographically progressive metastatic NETs (GI, pancreatic, or lung) receive a survivin-targeted long-peptide vaccine SurVaxM (SVN53-67/M57-KLH) with GM-CSF and Montanide alongside standard octreotide LAR. SurVaxM is designed to elicit survivin-specific CD8+/CD4+ T-cell and humoral responses; primary focus is safety and immunogenicity with preliminary antitumor activity assessed.

ClinicalTrials.gov ID: NCT03879694

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with metastatic or unresectable, MTAP‑deleted pancreatic ductal adenocarcinoma (measurable disease, adequate organs; no prior PRMT5/MAT2A inhibitors and, for the RAS combo, no prior MAPK/KRAS inhibitors) receive AMG 193, an oral MTA‑cooperative PRMT5 inhibitor exploiting MTAP synthetic lethality, combined with either gemcitabine/nab‑paclitaxel, modified FOLFIRINOX, or with RMC‑6236, an oral RAS(ON) tri‑complex inhibitor for RAS‑mutant cohorts. The study explores dose, safety, PK, and preliminary efficacy with expansion in defined PDAC cohorts.

ClinicalTrials.gov ID: NCT06360354

An Open-label, Phase I Trial With Expansion Cohort of Nab-Paclitaxel + Gemcitabine + Cisplatin + Botensilimab (AGEN1811) + Balsilimab (AGEN2034) + Chloroquine + Celecoxib in Patients With Previously Untreated Metastatic Pancreatic Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Previously untreated, metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) receiving triplet chemotherapy (nab-paclitaxel/gemcitabine/cisplatin) plus chloroquine and celecoxib, combined with dual checkpoint blockade: botensilimab (Fc‑engineered anti–CTLA‑4 designed to enhance T-cell priming/Treg depletion) and balstilimab (anti–PD‑1). Key exclusions include prior metastatic therapy, CNS mets, active autoimmune disease or prior checkpoint inhibitors, significant CV/GI disease, uncontrolled infections, retinal disease/G6PD deficiency, and warfarin/digoxin use.

ClinicalTrials.gov ID: NCT06076837

A Phase 1b/2 Trial of Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with untreated locally advanced unresectable or metastatic exocrine pancreatic adenocarcinoma (ECOG 0–1) receive NALIRIFOX plus oral onvansertib, a selective PLK1 inhibitor given days 1–5 each 14-day cycle. Key exclusions include significant cardiac risk/QTc prolongation, uncontrolled infection, untreated brain mets, GI absorption issues, strong CYP3A4/CYP2C19 modulators, and clinically significant effusions.

ClinicalTrials.gov ID: NCT06736717